Don't Go for the Goners

Recs

11

Editor's note: This article originally listed Generex Biotechnology as having received a “going concern” warning. Generex is a development-stage biotech that raises money in the public markets and uses the money to fund its R&D; in this case, the warning does not necessarily reflect poor financial condition.

It's undoubtedly been difficult for many individual investors to avoid the temptation to snap up shares of well-known companies now trading in the penny stock range. If you're one of them, I implore you: Don't give in without doing your homework. Most of those beaten-down stocks are in the dumps for good reason.

Despite a few signs of improvement, the macroeconomic climate has been brutal. Many consumers had too much debt. So did many companies. As a result, many companies will be blown right out of the water by the resulting massive deleveraging.

And now that consumers are dealing with plunging asset values, untenable debt, and increasing job losses, many companies' sales are understandably pinched, making it more difficult for them to service their own debt or borrow more to fund their operations. All of which makes for one seriously ugly domino effect.

Going, going, gone?
Last year, many people made wild bets on financial stocks like Fannie Mae, Freddie Mac, and Merrill Lynch. I'd guess that many of these folks unwisely ignored those companies' balance sheets, which are more important than ever in these troubled times. Indeed, these investors are still making wild bets; AIG (NYSE: AIG) has been a very popular stock for speculators, despite its high-profile troubles and reliance on government support.

The folly of shoddy due diligence has become evident in the increasing numbers of companies disclosing "going concern" warnings from their auditors. You can find those warnings in a company's quarterly (10-Q) or annual (10-K or 20-F) filings with the Securities and Exchange Commission. Usually, there will be a paragraph with language about factors that "raise substantial doubt as to our ability to continue as a going concern."

Need a well-publicized recent example of such a company? Look no further than CIT Group.

Cause for concern
When companies find it increasingly difficult to make ends meet, have negative cash flow, or can't find anybody to lend them money, auditors often eventually question their abilities to stay upright and in one piece. As you can imagine, such questions are popping up a lot more often these days.

Long-struggling Select Comfort (Nasdaq: SCSS) received such a warning related to its 2008 financials earlier this year, although it has since seen better days (and a big buy-in from a private equity firm). Escalon Medical and Allied Capital (NYSE: ALD) have both disclosed their own auditor warnings in recent memory.

Even though companies can and do take actions to fix these problems, such as amending credit agreements -- or, in Allied's case, being bought out by Ares Capital (Nasdaq: ARCC) -- the warning remains a dire sign that investors should take very seriously.

Accountants are usually reluctant to raise such red flags. According to a recent survey, only about half of companies that filed for bankruptcy in 2001 had actually received "going concern" warnings, and some companies that didn't actually ended up bankrupt anyway. A recent study by Duff & Phelps brought up that problem, noting that rapidly changing factors can make a company's ultimate fate hard to prognosticate.

Still, the proliferation of these warnings, and the reasons why companies fail -- obvious flaws such as lack of profitability and too much debt -- should lead investors to think twice about the beleaguered, supposedly "cheap" stocks they're choosing for their portfolios. There could be more spectacular flameouts on the way. Both the U.S economy and the average consumer are in bad shape, and many struggling, overindebted companies simply won't be able to survive.

Go for the gold, not for the goners
But plenty of stocks do represent strong companies with worthy management and little or no debt -- the kind of companies positioned to survive macroeconomic hardship while beleaguered rivals get taken out.

The team at Motley Fool Stock Advisor, which is beating the S&P by 42 percentage points on average, seeks only the highest-quality companies. Consider newsletter recommendation Berkshire Hathaway (NYSE: BRK-A) (NYSE: BRK-B). Prudent leadership by legendary investor and business mind Warren Buffett represents the gold standard in solid, well-led companies that are built to withstand the test of time.

However tempting the smorgasbord of beaten-down stocks may appear, let's all try to avoid too much speculative bravado. Go for the gold, not the goners. If you're looking for more stock ideas, you can click here to read more about the Stock Advisor team's favorite picks, free for the next 30 days.

Already a member of Stock Advisor? Log in at the top of this page.

This article was originally published on May 12, 2009. It has been updated.

Alyce Lomax does not own shares of any of the companies mentioned. Berkshire Hathaway is a Motley Fool Stock Advisor and an Inside Value pick. The Fool owns shares of Berkshire Hathaway and has a disclosure policy.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 30, 2009, at 8:59 AM, Fool wrote:

    Alot of Generex GNBT bashing going on these days. Very good sign as this usually leads to a nice run up in the stock price. Nice try though.

    Just like Jamba Juice. Watch that stock price rise in the near future. You can read these plays like a grade 1 level storytime book. :)

  • Report this Comment On October 30, 2009, at 1:08 PM, eewew wrote:

    What is this article on about? GNBT is doing extremely well. Yes they are a startup and trying to make ends meet but that's only so that they can progress their product.

    GNBT will be over $1 by the end of the year - no doubts about this.

  • Report this Comment On October 30, 2009, at 3:09 PM, mafgnbt wrote:

    Dear Ms. Lomax…

    I am contacting you regarding the article you authored that appears in today’s online edition (Oct 30 09) of The Motley Fool and, in particular, your comments about Generex Biotechnology Corporation (NasdaqCM : GNBT).

    Your comments betray a fundamental misunderstanding of basis accounting concepts in general and GNBT in particular.

    GNBT is a development-stage biotechnology corporation (“development-stage” has a specific accounting connotation). As such, GNBT has minimal revenue and its funds are expended in respect of research and development initiatives. Accordingly, and as mandated by basic GAAP, GNBT’s financial statements are prepared (and have been since its inception in 1998) on a “going concern” basis (as are the financial statements of any development-stage company in any industry). That basis of presentation is an accounting methodology and that approach does not necessarily reflect financial ill-health; and, as one who purports to make informed public comment on such matters, you ought to know that.

    The press release and Form 8-K Current Report filed by GNBT in respect of the so-called “going concern qualification” in the auditor’s report accompanying the July 31, 2009 annual financial statements included in GNBT’s Form 10-K Annual Report filed with the Securities and Exchange Commission earlier this month is merely a mandate of a Nasdaq rule. Regrettably, many people, like you, misapprehend that.

    As our press releases and filings with the SEC indicate, between May 15 09 and Sep 14 09 GNBT raised almost $34,000,000. Of that amount, $17,900,000 was raised subsequent to the Jul 31 09 fiscal year end to which the auditor’s report relates. As of today, GNBT has in excess of $28,000,000 in cash-on-hand. Furthermore, the Jul 31 09 financial statements indicate nominal indebtedness. Clearly, you made public comment on the financial health of GNBT (implying that it is a “goner”) without undertaking even a basic review of publicly available information on that subject and without contacting GNBT management for comment. That was inappropriate and irresponsible. Your comments have conveyed the erroneous impression that GNBT is in a precarious financial condition when, on the contrary, GNBT’s financial condition is robust.

    We request that you forthwith publish a retraction of your comments insofar as they were directed at GNBT to correct the misrepresentations you have made to the general public and capital markets participants in particular.

    Regards,

    Mark Fletcher

  • Report this Comment On October 30, 2009, at 9:00 PM, rjs9787 wrote:

    Ms Lomax's inadequete understanding of Generex's strong financial position aside, she also doesn't mention that she is discussing a research and development biotech with a potential blockbuster in worldwide Phase III trials. Generex's buccal insulin spray, Oral-lyn, should provide their company with substantial licensing opportunities once results confirm previous reports of a safe and effective alternative to injectable insulin.

    Of course, positive Phase III results do not always equate to the commercial viability of a new drug, as the product may not be accepted by diabetics in the marketplace. A little due diligence by Ms Lomax would reveal that strong eveidence already exists that diabetics will enthusiasticly accept Generex's novel buccal insulin spray. This evidence comes in the form of a Phase IV post marketing study by Generex's partner in India that was presented at a large diabetes industry event (IDF 2009) last week.

    Oral-lyn (marketed as Oral Recosulin in Inida) was safe, effective and "prefered" by a group of Type 2 diabetics that were failing with their current oral treatment. How many times do we ever hear of Type 2 diabetics prefering insulin therapy? Never. I believe future licensing partners will be able to comprehend what a Fool can not:

    IDF 20th World Diabetes Congress Oct 2009

    A 12 week phase IV study of recombinant human regular insulin metered dose buccal spray on subjects with type 2 diabetes who are suboptimally controlled while on oral antidiabetic agents

    P. Talwalkar1, A. Bhansali2, A. Jha3, R. Walia2, S. Gupta4, S. Srikanta5,

    Background: Evidence suggests that early insulin therapy for glycemic control provides additional benefits over conventional therapy in DM. However, subcutaneous route of administration is a barrier to initiating early insulin

    therapy in majority of these patients. Postprandial glucose control by buccal route of insulin administration may overcome this barrier, improve glycemic control and provide further benefits.

    Objective: This prospective open label phase IV multicentric study in India evaluated efficacy and safety of insulin metered dose buccal spray (Generex Oral-lyn™; Oral RecosulinTM) given pre- and post-meal in adult subjects with Type 2 DM that are suboptimally controlled with oral anti-diabetic agent (s).

    Methods: 40 Male and female insulin naïve type 2 adult diabetics, suboptimally controlled with oral anti diabetic agents (i.e. 6.5> HbA1c <8.5) but otherwise in good general health, received insulin in addition to their OHA,

    by metered dose buccal spray after training, in doses ranging from 4 to 10 puffs at each meal based on their FBG, for the study period of 3 months. The main outcome measures were improvement in glycemic control in terms of changes in HbA1c, and improvement in fasting and post meal glucose from baseline. Safety was assessed by monitoring changes from baseline in clinical

    and laboratory findings and changes in buccal cytology at the end of 3 months

    treatment.

    Findings: Findings in 40 type 2 diabetic patients on OHA who received metered dose buccal insulin spray showed improvement in glycemic control in terms of improvement in HbA1c values (Mean HbA1c value: 7.8% vs 7.3%)

    and fall in both fasting and postmeal glucose. No significant changes were observed in clinical laboratory events and buccal cytology. Except for minor

    hypoglycaemic episodes, transient burning sensations and transient numbness in mouth, no other adverse effects were observed. Recombinant human regular insulin metered dose buccal spray (Generex Oral-lyn™ ; Oral RecosulinTM)

    appears to be well tolerated and highly preferred by patients.

    Interpretation and conclusions: Treatment with insulin metered dose buccal spray (Generex Oral-lyn™; Oral RecosulinTM) in type 2 diabetes mellitus patients on OHA, resulted in glycemic improvement and was well tolerated. Oral Recosulin had high acceptability in patients.

    rjs9787

  • Report this Comment On November 01, 2009, at 8:35 PM, Fool wrote:

    I AM SICK OF YOU PEOPLE DOUBTING THIS COMPANIES ABILITY TO PERFORM. THEY HAVE

    PRESENTED THE FACTS. MS. ANNA GLUSKIN IS A TOP OF THE LINE BUSINESS WOMAN. I HAVE RESPECT FOR HER . SHE DOES NOT MAKE STATEMENTS UNLESS THEY ARE BACKED BY HER ACCOUNTANTS, FDA AND DECISION MAKERS OF THE COMPANY.

    THIS LITTLE COMPANY WILL COME FORTH, WILL SHINE AND MILLIONS OF PEOPLE

    AND CHILDREN WILL BE BLESSED .

    MAY GOD RICHLY BLESS THE CREATORS OF ORAL-LYN. THEIR WISDOM IS APPRECIATED.

  • Report this Comment On November 02, 2009, at 3:40 PM, smartparrothead wrote:

    Thank you Ms. Lomax as I was looking to add to my position.

Add your comment.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 1025927, ~/Articles/ArticleHandler.aspx, 11/23/2009 12:58:40 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
Buffett Bought Retail. Should You?

Related Tickers

11/23/2009 12:38 PM
AIG $35.27 Up +0.17 +0.48%
American Internati… CAPS Rating: **
ALD $3.60 Up +0.04 +1.12%
Allied Capital Cor… CAPS Rating: **
BRK-A $104030.99 Up +780.99 +0.76%
Berkshire Hathaway… CAPS Rating: *****
BRK-B $3466.77 Up +19.77 +0.57%
Berkshire Hathaway… CAPS Rating: *****
SCSS $5.49 Up +0.19 +3.55%
Select Comfort Cor… CAPS Rating: ***

Community: Investing Wiki

Term Of The Hour

Collection agency: A collection agency is an organization that specializes in the collection of overdue debts. They are best known for hassling people who owe money by telephone or in person with a knock on the door.

Want to learn more or edit this definition?
Click here to read more!